What is BridgeBio Pharma's net investment in lease?

BridgeBio Pharma (BBIO) reported net investment in lease of $17.23M in Q1 2026.

How has BridgeBio Pharma's net investment in lease changed year-over-year?

BridgeBio Pharma's net investment in lease increased by 140.4% year-over-year, from $7.17M to $17.23M.

What is the long-term trend for BridgeBio Pharma's net investment in lease?

Over 5 years (2020 to 2025), BridgeBio Pharma's net investment in lease has grown at a -13.2% compound annual growth rate (CAGR), from $16.51M to $8.15M.

BridgeBio Pharma BBIO Net Investment in Lease

Net Investment in Lease at other companies

Ionis PharmaceuticalsIONS

——

ALN

Alnylam PharmaceuticalsALNY

——

Revolution Medicines, Inc.RVMD

——

Roivant SciencesROIV

——

Arrowhead ResearchARWR

——

Neurocrine BiosciencesNBIX

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's net investment in lease?: BridgeBio Pharma (BBIO) reported net investment in lease of $17.23M in Q1 2026.
How has BridgeBio Pharma's net investment in lease changed year-over-year?: BridgeBio Pharma's net investment in lease increased by 140.4% year-over-year, from $7.17M to $17.23M.
What is the long-term trend for BridgeBio Pharma's net investment in lease?: Over 5 years (2020 to 2025), BridgeBio Pharma's net investment in lease has grown at a -13.2% compound annual growth rate (CAGR), from $16.51M to $8.15M.